Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01632-x
Abstract: Galcanezumab, a humanized monoclonal antibody that binds to calcitonin gene-related peptide, is approved for the preventive treatment of migraine in adults. It is self-administered once monthly as a subcutaneous injection. This paper describes the time… read more here.
Keywords: migraine; galcanezumab; maintenance; treatment ... See more keywords
Galcanezumab: First Global Approval
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-1002-7
Abstract: Galcanezumab-gnlm (Emgality™; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand. A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis. In September 2018,… read more here.
Keywords: migraine; galcanezumab; galcanezumab first; migraine adults ... See more keywords
Efficacy and safety of galcanezumab for cluster headache preventive treatment: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2024 at "Neurological Research"
DOI: 10.1080/01616412.2024.2440022
Abstract: ABSTRACT Background Galcanezumab is a monoclonal antibody targeting the CGRP pathway and represents the latest disease-specific and mechanism-based therapeutic option for cluster headache (CH). Objective We performed a systematic review and meta-analysis to evaluate the… read more here.
Keywords: meta analysis; meta; cluster headache; efficacy ... See more keywords
Galcanezumab for the prevention of cluster headache
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2020.1800635
Abstract: ABSTRACT Introduction Cluster headache (CH) is among the worst painful conditions. The available therapies are scarce and not specific, leaving many patients unsatisfied because of poor efficacy and/or tolerability. Patients not responding to common treatments… read more here.
Keywords: galcanezumab prevention; prevention cluster; cluster headache; galcanezumab ... See more keywords
Galcanezumab add-on in refractory cluster headache. A case series.
Sign Up to like & getrecommendations! Published in 2024 at "Pain management"
DOI: 10.1080/17581869.2024.2427564
Abstract: Cluster headache (CH), a highly disabling condition, lacks disease-specific, mechanism-based prophylactic treatment. Galganezumab, a monoclonal antibody targeting the calcitonin gene-related peptide, reduced the weekly attacks of CH in one randomized, placebo-controlled trial for the prevention… read more here.
Keywords: galcanezumab; treatment; case series; cluster headache ... See more keywords
100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies
Sign Up to like & getrecommendations! Published in 2018 at "Headache"
DOI: 10.1111/head.13427
Abstract: To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment. read more here.
Keywords: episodic migraine; galcanezumab; 100 response; response rate ... See more keywords
Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real-life multicenter study.
Sign Up to like & getrecommendations! Published in 2025 at "Headache"
DOI: 10.1111/head.15064
Abstract: BACKGROUND Patients with migraine aged ≥65 years old are underrepresented in clinical trials. This study compares effectiveness, excellent response, and tolerability of galcanezumab in patients ≥65 years and those younger than 65 years, specifically assessing age as a… read more here.
Keywords: age; excellent response; response; tolerability ... See more keywords
Real-world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2025 at "Headache"
DOI: 10.1111/head.70003
Abstract: OBJECTIVE This study aimed to summarize and pool real-world evidence on the clinical effectiveness and safety of galcanezumab. BACKGROUND Migraine is a disabling primary headache disorder. Several drugs that target calcitonin gene-related peptide, such as… read more here.
Keywords: effectiveness safety; real world; migraine; world ... See more keywords
Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
Sign Up to like & getrecommendations! Published in 2018 at "Cephalalgia"
DOI: 10.1177/0333102417747230
Abstract: Background Safety findings from a Phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (NCT02163993) are reported here. Methods Patients aged 18–65 years with episodic migraine were… read more here.
Keywords: phase; galcanezumab; treatment; study ... See more keywords
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
Sign Up to like & getrecommendations! Published in 2020 at "Cephalalgia"
DOI: 10.1177/0333102420905321
Abstract: Objective To report efficacy and safety of galcanezumab in adults with chronic cluster headache. Background Galcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide and inhibits its biological activity. Methods This study… read more here.
Keywords: galcanezumab; treatment; period; placebo ... See more keywords
Galcanezumab modulates Capsaicin-induced C-fiber reactivity
Sign Up to like & getrecommendations! Published in 2022 at "Cephalalgia"
DOI: 10.1177/03331024221112906
Abstract: Background The vasodilatory calcitonin-gene related peptide (CGRP) is understood as pivotal mediator in migraine pathophysiology. Blocking CGRP with small molecules or monoclonal antibodies (CGRP-mAb) reduces migraine frequency. However, prescription of CGRP-mAbs is still regulated and… read more here.
Keywords: capsaicin induced; blood flow; dermal blood; galcanezumab ... See more keywords